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Received January 10, 2012; accepted June 15, 2012AbstractBackground: Chronic cough related to eosinophilic inflammation has become an important cause of cough in recent years. Although fractional
exhaled nitrogen oxide (FeNO) measurement is an important monitoring tool, its lack of reference level may limit its usefulness. This study
aimed to determine the optimal FeNO level to guide inhaled corticosteroid (ICS) management in patients with chronic cough.
Methods: This retrospective study reviewed the medical records of patients with chronic cough for more than 8 weeks. Based on the selection
criteria, data were recalculated to determine the optimal cut-off value of FeNO for initiating ICS treatment in such patients.
Results: The medical records of 81 eligible patients were reviewed. Cough improved completely in 38 (Group A) of 44 patients who were treated
with ICS but not in the other six patients (Group B). In the 37 patients without ICS treatment, cough improved in 32 (Group C) by specific
treatment aimed at the possible causes of the cough, whereas the remaining five (Group D) had persistent cough. The patients were further
subdivided into Category 1 (all patients in Group A) and Category 2 (all patients in Groups B and C). Receiver operating characteristic analysis
showed that an FeNO of 33.9 ppb was the best cut-off value for using ICS (sensitivity 94.7%, specificity 76.3%) in patients with chronic cough.
In fourteen of 15 patients with bronchial hyperresponsiveness (BHR) or borderline BHR, the FeNO values were equal or higher than 33.9 ppb.
Obstructive ventilatory impairment was only seen in two patients.
Conclusion: Using FeNO measurement as a rapid, noninvasive diagnostic tool for patients with chronic cough, ICS can be prescribed if the
FeNO is 33.9 ppb or more.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: cough variant asthma; fractional exhaled nitric oxide; inhaled corticosteroid; nonasthmatic eosinophilic bronchitis; upper airway cough syndrome1. Introduction
Chronic cough is a complex problem with multiple causa-
tive factors. Patients are evaluated and managed in different
clinical settings, ranging from primary practice to varying
specialties, such as pulmonology, allergology, otorhinolaryn-
gology, and gastroenterology, in medical centers.1 Postnasal
drip syndrome, recently referred to as upper airway cough* Corresponding author. Dr. Ming-Chih Chou, Division of Chest Medicine,
Chung-Shan Medical University, 110, Section 1, Jianguo North Road, Tai-
chung 402, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2012.08.010syndrome (UACS),2 gastroesophageal reflux disease (GERD),
and cough variant asthma (CVA) are major causative factors in
nonsmokers with normal chest radiographs.3 In recent years,
nonasthmatic eosinophilic bronchitis (NAEB) has become an
important cause,4 characterized by the absence of airflow
obstruction and bronchial hyperresponsiveness (BHR),5 which
makes it difficult to diagnose. A recent review has demon-
strated that 10e66% of coughs are due to asthma/CVA/NAEB/
atopy,6 whereas another report states that NAEB may be the
cause of chronic cough in 10e30% of patients.7 Thus, for
patients with chronic cough, tests are recommended to
distinguish between noneosinophilic and eosinophilic cough
before initiating treatment.8hinese Medical Association. All rights reserved.
16 J.-Y. Hsu et al. / Journal of the Chinese Medical Association 76 (2013) 15e19A sputum differential cell count obtained from hypertonic
sputum induction is a good way to diagnose NAEB but is
time-consuming.9 Exhaled nitric oxide was first reported to be
elevated in asthmatic patients in 1993.10 Subsequent studies
have shown that fractional exhaled nitric oxide (FeNO)
measurement is a rapid, noninvasive, reproducible tool for
monitoring airway inflammation in asthmatic individuals.11,12
Due to the high prevalence of eosinophilic inflammation-
related cough, FeNO has been suggested for use in the
differential diagnosis of chronic cough.13 Hahn et al reported
that FeNO can be used to predict the response to inhaled
corticosteroid (ICS) treatment in chronic cough.14
Since FeNO level is ethnicity-dependent,15 the lack of
a national normal value may limit its usefulness. In a previous
work, the reference value for FeNO was determined as
27.9 ppb.16 Based on this result, an easy-to-remember FeNO
value (30 ppb) was adapted in the present study as a criterion
for initiating ICS treatment in patients with chronic cough.
The purpose of this study was to evaluate this criterion and to
determine an optimal FeNO level in chronic cough patients for
the initiation of ICS treatment.
2. Methods2.1. PatientsThe medical records of the patients who visited the asthma
and cough-specific clinic from June 1, 2007 to May 31, 2008
and who had had a history of chronic cough for more than
8 weeks were reviewed. Patients with obvious chest X-ray
abnormalities, who still smoked, or who had a smoking history
of more than 10 packeyears were excluded. The Institutional
Review Board of Taichung Veterans General Hospital
approved this retrospective study.
A stepwise approach and management protocol for chronic
cough was routinely used. The first step was 1e2 weeks of
a therapeutic trial period aimed at the specific complaints, such
as UACS or GERD. All patients except those who stopped
coughing after this period underwent FeNO measurement and
a methacholine provocation test to exclude those with
a possible diagnosis of classic asthma, CVA, or NAEB.
The response to treatment (i.e., complete control, improved,
not improved, or worsened) and the cause of the cough was
evaluated according to documentation in the medical records,
in which physicians made comments based on our routinely
used stepwise approach and management protocol for chronic
cough. The major cause of cough was defined by the most
effective treatment aimed at the related specific cause that was
able to alleviate the cough completely (complete control). For
diagnosing NAEB, a good response to ICS and an elevated
FeNO but no BHR were the mandatory criteria. For UACS,
improved symptoms of cough and upper airway symptoms
(rhinorrhea, nasal block, or postnasal drip) after antihistamine
or nasal corticosteroid (NCS) treatment was diagnostic. The
essential element for diagnosing GERD-related cough was
improved cough after proton pump inhibitor (PPI) treatment,
with or without the presence of reflux symptom or esophagitis.Online FeNO was measured using a chemiluminescence
nitric oxide analyzer (NOA 280i; Sievers, Boulder, CO, USA)
according to the American Thoracic Society/European Respi-
ratory Society recommendations.17 An expiratory flow rate of
50mL/s for at least 10 secondswith a plateau of at least 3 seconds
in duration was required. Three measurements were taken to
calculate the mean FeNO level, presented in parts per billion.
The methacholine challenge test was carried out using the
standard five-breath dosimeter method recommended by the
American Thoracic Society.18 The degree of BHR was deter-
mined by a provocative concentration that resulted in a 20%
fall (PC20) in forced expiratory volume in 1 second (FEV1).
Positive BHR was defined as PC20 < 4 mg/mL, negative BHR
as PC20 > 16 mg/mL, and borderline BHR as a PC20 between
4 and 16 mg/mL.
ICS treatment by Fluticasone Accuhaler (GlaxoSmithKline,
GreenfordMiddlesex,UK)with a 250mgper dose oral inhalation
of one puff twice daily was prescribed for at least 2 weeks if the
cough persisted after initial symptomatic treatment and if the
FeNO level was 30 ppb or more, if there was borderline to
positiveBHR, or if baseline ratio of FEV1 to forced vital capacity
was less than 70%.
For patients who did not receive ICS treatment or who still
had a cough despite ICS treatment, further diagnostic and
therapeutic steps, including NCS treatment for UACS or PPI
therapy for GERD, were carried out to evaluate other possible
causes. Details of other additional steps are not mentioned
here because they are beyond the scope of this study.2.2. Statistical methodsStatistical Package for the Social Sciences version 11.5
(SPSS Inc., Chicago, IL, USA) was used for statistical anal-
ysis. Continuous data were expressed as mean  standard
deviation. The nonparametric test KruskaleWallis H was used
to analyze the variables. A p value < 0.05 was considered
statistically significant. Receiver operating characteristic
(ROC) curve analysis and area under the curve (AUC) of ROC
analysis revealed an overall diagnostic accuracy and cut-off
value of FeNO that provided the highest sensitivity and
specificity. Specificity was calculated using Youden’s index
(defined as sensitivity þ specificity  1). Sensitivity was
plotted against false positivity (1  specificity) with the AUC
performance over the diagonal line (AUC 0.5) using 95%
confidence intervals (CIs).
3. Results
From 114 medical records reviewed, 26 patients were lost
to follow-up after the first visit, and seven stopped coughing
after the short-course (1e2 weeks) symptomatic treatment.
After exclusion of these 33 patients, the remaining 81 fulfilled
the inclusion criteria. Each one had validated data on FeNO
measurement and a methacholine provocation test before
further treatment was given. Of the 44 who received ICS
treatment, there was a complete improvement of cough in 38
(Group A) but no improvement in the remaining six (Group
Fig. 1. Patient flow according to the diagnostic and management protocol of
the study hospital. Inhaled corticosteroid treatment (ICS) resulted in complete
control of the cough in 38 patients (Group A). Six patients failed to respond to
ICS treatment (Group B). In 37 patients who did not receive ICS treatment,
cough improved in 32 patients with other treatments (Group C). Five patients
continued to have a cough without a known cause (Group D).
17J.-Y. Hsu et al. / Journal of the Chinese Medical Association 76 (2013) 15e19B). In the 37 patients without ICS treatment, cough improved
completely in 32 (Group C) after management aimed at the
specific cause (i.e., NCS for UACS and/or PPI for GERD).
The remaining five patients (Group D) with a persistent cough
were defined as having cough of unknown origin (Fig. 1).
From the general data on the 81 patients, there were 33
males and 48 females, with mean age of 49  14 years. Their
median duration of cough was 12 months (range 2e360
months), their mean FEV1 was 2.6  0.8 L (91.8  15.3%
predicted value), and their mean ratio of FEV1 to forced vital
capacity was 81.9  6.3% (Table 1). There was no difference
in age, duration of cough, or baseline spirometry data among
the groups.
Due to the uneven distribution of FeNO levels and frequent
presence of extremes or outliers, nonparametric statistical
analysis by KruskaleWallis test was used to calculate the
mean rank of the FeNO level. There was a significantTable 1
General data of the participants.
Group A Group B
n 38 6
Male/female 19/19 3/3
Age (y) 49  14 50  12
Median duration of cough
Months 12 36
Range 2e120 2e108
Mean FEV1, (L) 2.7  0.7 2.8  0.9
Mean FEV1 (% predicted) 89.1  13.3 97.4  15.1
Mean FEV1/FVC ratio 81.7  7.3 79.5  6.2
Mean rank FeNO (ppb)a 57.1 59.2
Group A ¼ cough improved after inhaled corticosteroid (ICS) treatment; Group B ¼
ICS treatment; Group D ¼ unknown cause of cough.
FeNO ¼ fractional exhaled nitrogen oxide; FEV1 ¼ forced expiratory volume in
a By KruskaleWallis test.difference in FeNO levels among the groups. Owing to the
small case numbers in Groups B and D, only the difference in
mean rank of FeNO levels between Group A (57.1 ppb) and
Group C (22.4 ppb) was presented ( p < 0.005) (Fig. 2).
Because an FeNO value of 30 ppb was the arbitrarily
chosen cut-off value for initiating ICS treatment, data were
subsequently analyzed and the patients were divided into two
categories: Category 1 (all patients in Group A, whose cough
was controlled completely by ICS) and Category 2 (all patients
in the Groups B and C, whose cough did not improve after ICS
treatment or whose cough improved completely without ICS).
After this adjustment, the number of patients with an elevated
FeNO level was reduced from 51 to 45 (Table 2). The ROC
analysis determined that an FeNO of 33.9 ppb was the best
cut-off value for using ICS (sensitivity 94.7%, specificity
76.3%; AUC 0.86; 95% CI 77.1e94.9%) (Fig. 3).
In terms of causes of cough, 53% of patients had multiple
(at least two) causative factors (Table 3). The three leading
causes of chronic cough were UACS (n ¼ 31; 38.2%), NAEB
(n ¼ 27; 33.3%), and CVA/borderline BHR (n ¼ 14; 17.3%).
In contrast to the high occurrence rate of NAEB, classic
asthma with obstructive ventilatory impairment was relatively
rare (n ¼ 2; 2.5%). Although GERD was a frequent complaint
(n ¼ 26; 32.1%), it was not a major cause of cough (being seen
in only two patients).4. Discussion
The evaluation and management of chronic cough of
unknown origin is a complicated task. The stepwise algorithm
used in the present study helps to reduce the probability of
missing the diagnosis. Although some biases may exist, the
data obtained from this study represent real-life experiences,
which may be valuable when facing patients with a history of
long-term cough.
The FeNO level reportedly correlates with sputum eosin-
ophils or eosinophilic count obtained by bronchoalveolar
lavage.19 This makes it possible for FeNO measurement to be
an alternative method of evaluating eosinophilic airway
inflammation in patients with asthma or chronic cough. OneGroup C Group D All
32 5 81
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Fig. 3. The receiver operating characteristic (ROC) curve was used to assess
the diagnostic accuracy and cut-off value of fractional exhaled nitrogen oxide
(FeNO) level in patients with cough. The area under the curve was 0.86. An
FeNO of 33.9 ppb showed the best sensitivity (94.7%) and specificity (73.8%)
in predicting the effect of inhaled corticosteroids for the treatment of chronic
cough.
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Fig. 2. The fractional exhaled nitrogen oxide (FeNO) level in the different
patient groups. The transverse bars within the boxes represent the median
FeNO level for each group; shaded boxes represent the 95% confidence
intervals. B ¼ outliers; O ¼ extremes.
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CVA, with 75% sensitivity and 87% specificity.20 Another
study suggested that NAEB could be excluded if FeNO was
less than 32 ppb in patients with a chronic cough.21 On the
other hand, an FeNO of 47 ppb was reported as the lower limit
for predicting corticosteroid response in chronic cough in
a further study.22
It is known that FeNO level is ethnicity-dependent.15 As
such, the lack of a national normal value may limit its
usefulness. A previous study showed that the reference normal
value for FeNO was 27.9 ppb.16 This is the basis for adopting
the easy-to-remember 30 ppb of FeNO as the cut-off value in
this study. However, ROC analysis after subdividing the
patients into two categories revealed that an FeNO of 33.9 ppb
is a better cut-off value than one of 30 ppb for predicting the
response to ICS treatment. Even if there is a minimal decrease
in sensitivity (from 97.4% to 94.7%), the increase in speci-
ficity (from 65.8% to 76.3%) is more pronounced. These
changes have been made from the regrouping of one patient in
Group A (FeNO level 31.4 ppb) and five in Group C (FeNO
level range 30e32.3 ppb). Although these cut-off data are not
derived from a randomized control trial, they may be useful in
future for determining the timing of ICS treatment in chronic
cough.Table 2
Fractional exhaled nitrogen oxide (FeNO) level and results of treatment.
FeNO
(ppb)
Category 1 Category 2 Total
Group A (n) Group B (n) Group C (n) Group D (n)
30 37 6 8 0 51
<30 1 0 24 5 30
33.9 36 6 3 0 45
<33.9 2 0 29 5 36
FeNO cut-off value 30 ppb¼ sensitivity 0.974, specificity 0.658; FeNO cut-off
value 33.9 ppb ¼ sensitivity 0.957, specificity 0.763. Category 1 ¼ all patients
in Group A; Category 2 ¼ all patients in Groups B and C.In the present study, the causes of cough were identified not
only from the history and physical examination, but also from
the response to the specific treatment aimed at the possible
causes. It was a unexpected finding that the number of the
patients with elevated FeNO was surprisingly high, and only
two patients had obstructive ventilatory impairment (2.5%).
The use of bronchodilators in patients with chronic cough is
controversial.23 Sun et al reported that oral bronchodilators are
frequently used as the primary treatment method for chronic
cough, especially in pediatric patients.24 However, the oral
beta-2 agonist albuterol is not recommended for patients with
acute, nonspecific coughs.25 Inhaled salbutamol has been
proven to be no different from placebo in treating cough in
pediatric patients.26 Nevertheless, Irwin et al have demon-
strated that an improvement in cough with bronchodilator
treatment is diagnostic of CVA,27 while the Japanese Respi-
ratory Society guidelines for the management of cough
suggest that long-acting beta-2 agonist or slow-release
theophylline should be added to the treatment regimen forTable 3
The causes of chronic cough.
Major Second Third All
Nonasthmatic eosinophilic bronchitis 27 16 1 44
Cough variant asthma 2 0 0 2
Borderline bronchial hyperresponsiveness 12 0 0 12
Classic asthma 2 0 0 2
Upper airway cough syndrome 31 21 9 61
Gastroesophageal reflux disease 2 15 9 26
Other 5 0 0 5
One cause of cough: n ¼ 38; two causes of cough: n ¼ 34; three causes of
cough: n ¼ 9. Major ¼ major cause of cough; Second ¼ secondary cause of
cough; Third ¼ tertiary possible cause of cough.
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cough in two patients who presented with obstructive venti-
latory impairment was controlled by combined ICS plus
a long-acting beta-2 agonist.
The result of the bronchial provocation test showed
a PC20< 16mg/mL in 14 patients. Although positive test results
(PC20< 4mg/mL)were seen in only two patients, the remaining
patients had borderline positive findings. By definition, these 12
were not classified as having CVA or NAEB, but their treatment
was unaffected since they all had elevated FeNO levels.
In conclusion, this study confirms that eosinophilic
inflammation of the airways is common in patients with
chronic cough. FeNO measurement is a rapid and noninvasive
tool that should be available in the clinic for evaluating the
causes of chronic cough, and ICS treatment is indicated if the
FeNO level is higher than 33.9 ppb. Further studies are indi-
cated to validate the FeNO level and the percentage of sputum
eosinophils.References
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